期刊文献+

大剂量化疗治疗高危和复发转移性乳腺癌致粒细胞缺乏症并发热的临床分析 被引量:7

Clinical analysis of high-risk primary and metastatic breast cancer patients with neutropenia and fever after high-dose chemotherapy
原文传递
导出
摘要 目的:探讨高危和复发转移性乳腺癌大剂量化疗后粒细胞缺乏症并发热的发生率、感染及病原菌和治疗措施。方法:收集2004-07-2009-04我科高危和复发转移性乳腺癌进行大剂量化疗病例共145例,分析其临床资料。结果:高危和复发转移性乳腺癌大剂量化疗后粒细胞缺乏症发生率97.2%(141/145)。发热的发生率57.2%(83/145),持续(3.37±1.77)d。发热组和未发热组的中位最低中性粒细胞数分别为0.000×109L-1和0.026×109L-1,χ2=4.563,P=0.033;平均粒细胞缺乏持续时间分别为4.75和3.26 d,t=4.409,P=0.000。微生物学证实的感染病例占8.4%(7/83),临床诊断的感染病例占56.6%(47/83),不明原因发热病例占34.9%(29/83)。常见感染部位咽、口腔和舌体病例占28.9%(24/83),胃肠道病例占24.1%(20/83)。主要病原菌为革兰阴性菌42.9%,经验性抗生素治疗有效率为100.0%。结论:高危和复发转移性乳腺癌大剂量化疗后具有极高的粒细胞缺乏症和发热的发病率,多于1周内出现,持续3~4 d。消化道是其常见感染部位,以革兰阴性菌为主。综合性防治措施有效。 OBJECTIVE:To explore the incidence of febrile neutropenia(FN),infection,major pathogens,and treatment measures for high-risk primary and metastatic breast cancer patients after high-dose chemotherapy.METHODS:Totally 145 cases of high-dose chemotherapy in high-risk primary and metastatic breast cancer patients from July 2004 to April 2009 were reviewed and analyzed their clinical data was analyzed.RESULTS:The incidence of neutropenia in high-risk primary and metastatic breast cancer patients after high-dose chemotherapy was 97.2%(141/145).The incidence of FN was 57.2%(83/145),and the duration of fever was(3.37±1.77) days.The median low nadir of ANC was 0.000×10^9 L^-1 and 0.026×10^9 L^-1 in the fever and normal groups,respectively(χ^2=4.563,P=0.033),with the mean duration of neutropenia of 4.75 days vs.3.26 days(t=4.409,P=0.000).There were 8.4%(7/83) microbiologically documented infections,56.6%(47/83) clinically suspected infections and 34.9%(29/83) FUO.The most common focus of infection was the pharynx,mouth and tongue(28.9%) followed by the gastrointestinal tract(24.1%).Gram-negative microorganisms were the most frequently isolated agents(42.9%).The overall response rate to empirical antibiotherapy was 100.0%.CONCLUSIONS:There are very high incidences of neutropenia and FN in high-risk primary and metastatic breast cancer patients receiving high-dose chemotherapy,frequently occur in a week for 3 to 4 days.Digestive tract is the common sites of infection,and gram-negative bacteria are the main pathogens.Comprehensive treatment measures are effective.
出处 《中华肿瘤防治杂志》 CAS 2010年第24期2045-2048,共4页 Chinese Journal of Cancer Prevention and Treatment
基金 首都医学发展科研基金(2007-2053)
关键词 乳腺肿瘤/药物疗法 大剂量化疗 发热 粒细胞缺乏症 感染 breast neoplasms/drug therapy fever neutropenia infection
  • 相关文献

参考文献10

  • 1NCCN clinical practice guidelines in oncology TM. Prevention and treatment of cancer-related infections (v. 2. 2009).
  • 2医院感染诊断标准(试行)[J].中华医学杂志,2001,81(5):314-320. 被引量:5953
  • 3Crump M, Gluck S, Tu D,et al. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA. 16[J]. J Clin Oncol, 2008, 26(1):37-43.
  • 4Biron P, Durand M, Roche H, et ah Pegase 03: a prospective randomized phase Ⅲ trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer[J].Bone Marrow Transplant, 2008, 41(6):555-562.
  • 5Lotz J P, Cure H, Janvier M, et al. High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol [J]. Eur J Cancer, 2005,41(1):71-80.
  • 6Genser S, Salepsi T, Ozer S. Evaluation of infectious etiology and prognostic risk factors of febrile episodes in neutropenic cancer patients[J]. J Infect, 2003,47(1) :65-72.
  • 7Hughes W T, Armstrong D, Bodey G P, et al. 2002 guidelines for the use of antimicrohial agents in neutropenie patients with cancer[J]. Clin Infect Dis, 2002,34(6) : 730-751.
  • 8Curry M P, Afdhal N H. Use of growth factors with antiviral therapy for chronic hepatitis C[J]. Clin Liver Dis, 2005,9(3):439 -451.
  • 9Kuderer N M, Dale D C, Crawford J, et al. Mortality, morbidity, and eostassociated with febrile neutropenia in adult cancer patients[J]. Cancer, 2006, 106(10):2258-2266.
  • 10汪复,朱德妹,胡付品,阮斐怡,倪语星,孙景勇,徐英春,张小江,胡云健,艾效曼,俞云松,杨青,孙自镛,简翠,贾蓓,黄文祥,卓超,苏丹虹,魏莲花,吴玲,张朝霞,季萍,王传清,薛建昌,张泓,李万华.2008年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志,2009,9(5):321-329. 被引量:423

二级参考文献12

  • 1王辉,郭萍,孙宏莉,杨启文,陈民钧,朱元珏,徐英春,谢秀丽.碳青霉烯类耐药的不动杆菌分子流行病学及其泛耐药的分子机制[J].中华检验医学杂志,2006,29(12):1066-1073. 被引量:237
  • 2Clinical and I.aboratory Standards Institute(CLSI). Perform ance standards for Antimicrobial susceptibility testing[S]. M100-S17, 2007.
  • 3Clinical and Laboratory Standards Institute (CLSI). Perform anee standards for Antimicrobial susceptibility testing [S]. M100-S19,2009.
  • 4Bratu S, I.andman D, Haag R, et al. Rapid spread of carbapenem resistant Klebsiella pneumoniae in New York City: anew threat to our antibiotic armamentarium[J]. Arch Int Meal.2005,165(12) :1430-1435.
  • 5Endimiani A, Hujer AM, Perez F, et al. Characterization of blaKPC containing Klebsiella pneumoniae isolates detected in different institutions in the eastern USA [J]. J Antimierob Chemother, 2009, 63(3):427-437.
  • 6Jeon BC, Jeong SH, Bae IK, et al. Investigation of a nosocomial outbreak of imipenem resistant Acinetobacter baumannii producing the OXA- 23 β- lactamase in Korea[J]. J Clin Microbiol, 2005, 43(5):2241 -2245.
  • 7NaasT, LevyM, HirschauerC, et al. Outbreak ofcarbapen em resistant Acinetobacter baumannii producing the carbap enemase OXA- 23 in a tertiary care hospital of Pepcete, French Polynesta[J]. J Clin Mierohiol, 2005, 43 (9) : 4826- 4829.
  • 8Waites KB, Dully LB, Dowzicky MJ. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and invitro activity of tigecycline, a new glycylcycline antimicrobial[J]. Antimicrob Agents Chemother, 2006,50(10):3479- 3484.
  • 9Souli M, Kontopidou FV, Koratzanis E, et al. lnvitro activity of tigecycline against multiple-drug resistant, including pan resistant, Gram negative and Gram-positive clinical isolates from Greek hospitals[J]. Antimicrob Agents Chemother, 2006.50(9) :3166- 3169.
  • 10Gordon NC, Warehan, DW. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline [J]. J Antimicrob Chemother, 2009, 63(4) :775-780.

共引文献6369

同被引文献35

  • 1屈元姣,刘陶文,徐李容,曹轶林.肿瘤化疗后中性粒细胞缺乏症的临床综合治疗[J].广西医科大学学报,2009,26(6):939-940. 被引量:4
  • 2郭小毛,梅欣,章倩.局部晚期乳腺癌的治疗进展[J].中国癌症杂志,2006,16(6):409-416. 被引量:35
  • 3Yao S, Barlow WE, Albain KS, et al. Gene Polymorphisms in cy- clophosphamide metabolism pathway, treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breastcancer[J]. Clin Cancer Res,2010,16(24)6169-6171.
  • 4Xie HJ,Griskevicius L, Stahle L, et al. Pharmacogenetics o{ cy- clophosphamide in patients with hematological malignancies. Eur J Pharm Sci, 2006,27 (1) : 54-61.
  • 5Nakajima M, Komagata S, Fujiki Y, et al. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclo- phosphamide in Japanese cancer patients[J. Pharmacogenetics Ge- nomics, 2007,17 (6) 431-444.
  • 6Timm R,Kaiser R, Lotsch J,et al. Association of cyclophospha- mide pharmacokinetics to polymorphic eytoehrome P450 2C19[J]. Pharmacogenomies J,2005,5(6) :365-373.
  • 7Ekhart C,Doodeman VD,Rodenhuis S, et al. Influence of poly- morphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDHIA1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4 hydroxycyclophosphamideJ. Pharmacogenet Genomics, 2008, 18(6) :515-523.
  • 8Marsh S,Paul J,King CR, et al. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish randomised trial in ovarian cancer[J]]. J ClinOneol,2010,25(29):4528-4535.
  • 9Nakamura Y. Pharmacogenomies and drug toxicityJ]. N Engl J Med,2008,359(8) =856-858.
  • 10NCCN clinical practice guidelines in oncologyTM. Prevention and treatment of cancer-related infections(v. 1. 2011 ) [ EB/OL]. ht- tp ://www. nccn. org/professionals/physician_gls/f_guidelines, asp infections.

引证文献7

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部